ACRS Aclaris: Multiplikator Forward P/S

Aclaris Therapeutics (ACRS) relies on financial reserves due to a lack of sales, which is confirmed by the expected P/S ratio shown on GURU.Markets, where the current parameter equals 91.90. Diversification through dermatological and rheumatological projects mitigates risks; however, business success depends on licenses and clinical trial outcomes, creating a threat of capital deficiency.
Rincian metrik lan analitis perusahaan aclaristx.com (ACRS)

This indicator is calculated as the ratio of Aclaris Therapeutics (ACRS) current market capitalization to projected revenue, allowing for the real-time tracking of market expectations between quarterly reports. The expected P/S ratio reflects investor confidence in future sales, which for biopharmaceuticals is critically dependent on the stability of raw material supplies from Asia and the success of international clinical trials.